Inhibitory Constituents against HIV-1 Protease from Agastache rugosa

Byung Sun Min^{1,2}, Masao Hattori², Hyeong Kyu Lee³ and Young Ho Kim^{1,*}

¹College of Pharmacy, Chungnam National University, Taejon 305-764, Korea, ²Research Institute for Traditional Sino-Japanese Medicines, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan and ³Korea Research Institute of Bioscience & Biotechnology, Taejon 305-600, Korea

(Received September 21, 1998)

Two diterpenoid compounds, agastanol (1) and agastaquinone (2), were isolated from the roots of *Agastache rugosa* (Labiatae). Compound 1 and 2 showed significant inhibitory effects against human immunodeficiency virus type 1 (HIV-1) protease activity with IC₅₀ values of 360 and 87 μ M, respectively.

Key words: Agastache rugosa, Labiatae, Agastanol, Agastaquinone, Anti-HIV-1 protease activity

INTRODUCTION

The cure and prevention of acquired immunodeficiency syndrome (AIDS) has been a global challenge since it was discovered, but nontoxic and less side effect anti-AIDS drugs are still in demand. Most of the developments for anti-AIDS drugs are based on blocking the steps of the viral life cycle, such as adsorption of the virus particle to the host cell, synthesis of viral DNA by reverse transcriptase, viral proteolytic process by protease and synthesis of viral envelope glycoproteins (Mitsuya et al., 1987). The polyproteins are proteolytically processed by the action of a virus-encoded protease and created the functional proteins (Henderson et al., 1988). Therefore, the inhibition of HIV-1 protease has been a promising target for the development of antiviral agents for AIDS (Ido et al., 1991). In order to find HIV-1 protease inhibitory substances from natural products, we isolated several compounds from Areca catechu, (Kusumoto et al., 1995), Swietenia mahagoni (Matsuse et al., 1997) and Ganoderma lucidum (El-Mekkawy et al., 1988; Min et al., 1998). In the continuing study, we found that agastanol (1) and agastaquinone (2) from Agastache rugosa showed the inhibitory activities against HIV-1 protease.

MATERIALS AND METHODS

General experimental procedures

Melting points were obtained with an Electrothermal Series IA9100 apparatus and were not corrected. UV

Correspondence to: Young Ho Kim, College of Pharmacy, Chungnam National University, Taejon 305-764, Korea

spectra were taken in *n*-hexane and MeOH on a Milton-Roy Spectronic 3000 spectrophotometer. IR spectra were recorded on a Precision Analect RFX-65 spectrophotometer. Mass spectra were obtained on a Kratos Concept-1S spectrometer at 70 eV. ¹H- and ¹³C-NMR experiments were run in CDCl₃ containing TMS as the internal standard, using Varian Unity-300 and Bruker AM-500 spectrometers. Elemental analysis was carried out with a Carlo Erba EA1108 elemental analyzer.

Plant material

The roots of *A. rugosa* were collected at Yangsan (Kyongnam Province, Korea) in October 1992. The voucher specimen are deposited in the Korea Research Institute of Bioscience and Biotechnology (KRIBB), Korea.

Extraction and isolation

The air-dried roots (4.5 kg) of *A. rugosa* were ground and extracted with methanol (10 liters x 3) followed by a mixture of *n*-hexane-EtOAc-Me₂CO (4:4:2) (8 liters, 3×) at room temperature. The combined extracts were concentrated and extracted with *n*-hexane (500 ml, 4×). From *n*-hexane extract (50 g), agastanol (1, 160 mg) and agastaquinone (2, 150 mg) were isolated from repeated column chromatography and recrystallization method.

Agastanol (1): Pale yellow needle crystals (*n*-hexane). mp 180~182°C. $C_{21}H_{28}O_4$ (Found: C 72.88%, H 8.08, Calcd.: C 72.23%, H 8.17%). CIMS m/z: 345 (MH⁺), EIMS m/z: 344 (M⁺, base peak). UV λ_{max} (MeOH): 240, 279, 372. IR ν_{max} KBr (cm⁻¹): 3360, 2960, 1612. ¹H-and ¹³C-NMR data: see reference (Lee *et al.*, 1994).

Agastaquinone (2): dark red needles, mp 121~122°, $C_{20}H_{20}O_5$ (Found: C 70.78%, H 6.05%, Calcd.: C 70.59%, H 5.88%). UV λ_{max} (MeOH, log ε): 235 sh (3.91), 296 (3.93), 340 (3.51), 454 (3.46). IR ν_{max} KBr (cm⁻¹): 2973, 1668, 1658, 1630, 1610, 1292, 1275, 1259, EIMS m/z (rel. int.): 340 (M⁺, 100). ¹H- and ¹³C-NMR data: see reference (Lee et al., 1995).

Protease assay

Twenty five µl of HIV-1 protease assay buffer (Bachem HIV protease assay Kit S-1000) containing 2.5 µg of a substrate, His-Lys-Ala-Arg-Val-Leu-(pNO2-Phe)-Glu-Ala-NLe-Ser-NH₂, was mixed with 2.5 µl of a dimethyl sulfoxide (DMSO) solution of test compound, then 2.5 μl of recombinant HIV 1-protease (0.175 μg protein) was added to the mixture. After incubation at 37°C for 20 min, the reaction was stopped by addition of 2.5 µl of 10% TFA. The hydolysate and the remained substrate were quantitatively analyzed by HPLC under the following conditions: column, RP-C18 (150×4.6 mm i.d., YMC Co.); elution, a linear gradient of CH₃CN (20~ 40%) in 0.1% TFA; injection volume, 5 μl; flow rate, 1.0 ml/min; detection, 280 nm. The hydrolysate and substrate were eluted at 5.1 and 10.8 min, respectively. The inhibitory activity of the compound in the HIV-1 protease assay was calculated as follows: % inhibition= $100 \times (A_{control} - A_{sample})/(A_{control})$; where A is a relative peak area of the hydrolysate. Acetyl pepstatin was used as a positive control with an IC₅₀ of 0.24 μM under the above conditions.

RESULTS AND DISCUSSION

The whole plant of *A. rugosa* has been used as an agent for the treatment of cholera, vomiting, and miasma. It is considered useful in treating influenza or colds, headache, indigestion, fever, cholera and the nausea of pregnancy. In previous study, we isolated two new diterpenoid compounds, agastanol (1) and agastaquinone (2), from the roots of *A. rugosa*. Agastanol (1), pale yellow needles, mp 180~182°C, C₂₁H₂₈O₄, showed cytotoxic activities (ED₅₀: 4.9~29.9 ug/ml) against several human cancer cells (A549, SK-OV-3,

Fig. 1. Structures of agastanol (1) and agastaquinone (2)

Table I. HIV-1 protease inhibitory activities of compound **1** and **2**

IC ₅₀ (μM)
360
87
0.24

^aPositive control

SK-MEL-2, XF498 and HCT15). It showed weak antifungal activity against Trichopyton rubrum (Lee et al., 1994). Agastaquinone (2), dark red needles, mp 121~122 °C, C₂₀H₂₀O₅, showed nonspecific cytotoxic activities (ED₅₀: 1.8~12.8 ug/ml) against same human cancer cell lines in vitro (Lee et al., 1995). They were tested for the inhibitory activities against HIV-1 protease. The compound 1 showed weak inhibitory activity with IC50 value of 360 μM. While compound 2 showed significant inhibitory activity with IC50 value of 87 μM (Table II). Both case of cytotoxicity assay and HIV-1 protease assay, quinone compound, agastaquinone (2), showed higher cytotoxic effect against human cancer cell lines and inhibitory activity on HIV-1 protease than hydroxyl compound, agastanol (1). The active mechanism of quinone moiety in diterpene compound will be of particular interest to be investigated in future. In natural products, several diterpene compounds have been described as antiviral compounds. Prostatin, a phorbol ester type, showed potent anti-HIV activity without tumor-promoting effect (Gustafson et al., 1992). Tripterifordin and neotripterifordin from Tripterygium wilfordii inhibited HIV-1 in H9 lymphocyte cells (Chen et al., 1992, 1995). 6-Hydroxytremetone from Werneria cilliolata showed a significant inhibition of HIV-1 replication (Piacente et al., 1994). Based on the inhibitory activities against HIV-1 protease from natural products, more detailed study will be needed to clarify the action of diterpenoid compounds from A. rugosa.

REFERENCES CITED

Chen, K., Shi, Q., Fujioka, T., Zhang, D. C., Hu, C. Q., Jin, J. Q., Kilkuskie, R. E., and Lee, K. H., Anti-AIDS agents 4. Tripterifordin, a novel anti-HIV principle from *Tripterygium wilfordii*: isolation and structural elucidation. *J. Nat. Prod.*, 55, 88-92 (1992).

Chen, K., Shi, Q., Fujioka, T., Nakano, T., Hu, C. Q., Jin, J. Q., Kilkuskie, R. E., and Lee, K. H., Anti-AIDS agents 4. Neotripterifordin, a novel anti-HIV principle from *Tripterygium wilfordii*: isolation and structural elucidation. *Bioorg. Med. Chem.*, 3, 1345-1348 (1995).

El-Mekkawy, S., Meselhy, M. R., Nakamura, N., Tezuka, Y., Hattori, M., Kakiuchi, N., Shimotohno, K., Kawahata, T., and Otake, T., Anti-HIV and anti-HIV-protease substances from *Ganoderma lucidum*.

- Phytochemistry, in press (1998).
- Gustafson, K. R., Cardellina II, J. H., McMahon, J. B., Gulakowski, R. J., Ishitoya, J., Szallasi, Z., Lewin, N. E., Blumberg, P. M., Weislow, O. S., Beutler, J. A., Buckheit Jr., R. W., Cragg, G. M., Cox, P. A., Bader, J. P., Boyd, M. R., A non-promoting phorbol from the Samoan medicinal plants, *Homalanthus nutans*, inhibits cell killing by HIV-1. *J. Med. Chem.*, 35, 1978-1986 (1992).
- Henderson, L. E., Benveniste, R. E., Sowder, R., Copeland, T. D., Schultz, A. M., and Oroszlan, S., Molecular characterization of gag proteins from simian immunodeficiency virus (SIV_{Mne}). J. Virol., 62, 2587-2585 (1988).
- Ido, E., Han, H. P., Kezdy, F. J., and Tang, J., Kinetic studies of human immunodeficiency virus type I protease and its active-site hydrogen bond mutant A28S. *J. Biol. Chem.*, 266, 24359-24366 (1991).
- Kusumoto, I. T., Nakabayashi, T., Kida, H., Miyashiro, H., Hattori, M., Namba, T., and Shimotohno, K., Screening of various plants extracts used in Ayurvedic medicine for inhibitory effects on human immunodeficiency virus type-1 (HIV-1) protease. *Phytother. Res.*, 9, 180-184 (1995).
- Lee, H. K., Byon, S. J., Oh, S. R., Kim, J. I., Kim, Y. H.,

- and Lee C. O., Diterpenoids from the roots of *Agastache rugosa* and their cytotoxic activities. *Kor. J. Pharmacog.*, 25, 319-327 (1994).
- Lee, H. K., Oh, S. R., Kim, J. I., Kim, J., Lee, C. O., Agastaquinone, a new cytotoxic diterpenoid quinone from *Agastache rugosa*. *J. Nat. Prod.* 58, 1718-1721 (1995).
- Matsuse, I. T., Nakabayashi, T., Lim, Y. A., Hussein, G., Miyashiro, H., Kakiuchi, N., Hattori, M., Stardjo, S. and Shimotohno, K., A human immunodeficiency virus protease inhibitory substance from *Swietenia mahagoni*. *Phytother. Res.*, 11, 433-436 (1997).
- Min, B. S., Nakamura, N., Miyashiro, H., Bae, K. H., and Hattori, M., Triterpenes from the spores of *Ganoderma lucidum* and their inhibitory activity against HIV-1 protease. *Chem. Pharm. Bull.*, 46, 1607-1612 (1998).
- Mitsuya, H., and Broder S., Strategies for antiviral therapy in AIDS. *Nature* 325, 773-778 (1987).
- Piacente, S., Aquino, R., De Tommasi, N., Pizza, C., Lock De Ugaz, O., Chevez Orellana, H., and Mahmood, N., Constituents of *Werneria ciliolata* and their *in vitro* anti-HIV activity. *Phytochemistry*, 36, 991-996 (1994).